| Literature DB >> 36193427 |
Erkan Ozduran1, Sibel Büyükçoban2.
Abstract
Background: The use of the internet as a source of information has increased during the pandemic, and YouTube has become an increasingly important source of information on Coronavirus disease 2019 (COVID-19). In the long COVID picture, which occurs when symptoms related to COVID-19 last longer than 1 month, pain involving the musculoskeletal system affects the quality of life quite negatively. The aim of this study was to investigate the informational value and quality of YouTube videos related to post-COVID pain.Entities:
Keywords: COVID-19; E-learning; Pain; Post-acute COVID-19 syndrome; YouTube
Year: 2022 PMID: 36193427 PMCID: PMC9526419 DOI: 10.7717/peerj.14089
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 3.061
Contents of JAMA, DISCERN and GQS assessment criteria.
| JAMA benchmark criteria | Total score (0–4 points) |
|---|---|
| Authorship | 1 Point (Authors and contributors, their affiliations, and relevant credentials should be provided) |
| Attribution | 1 Point (References and sources for all content should be listed) |
| Disclosure | 1 Point (Conflicts of interest, funding,sponsorship, advertising, support, and video ownership should be fully disclosed) |
| Currency | 1 Point (Dates that on which the content was posted and updated should be indicated). JAMA is used to evaluate the accuracy and reliability of information) |
|
|
|
| 1 Are the aims clear? | 1–5 point |
| 2 Does it achieve its aims? | 1–5 point |
| 3 Is it relevant? | 1–5 point |
| 4 Is it clear what sources of information were used | 1–5 point |
| 5 Is it clear when the information used or reported in the publication was produced? | 1–5 point |
| 6 Is it balanced and unbiased? | 1–5 point |
| 7 Does it provide details of additional sources of 1.45 support and information? | 1–5 point |
| 8 Does it refer to areas of uncertanity? | 1–5 point |
| 9 Does it describe how each treatment works? | 1–5 point |
| 10 Does it describe the benefits of each treatment? | 1–5 point |
| 11 Does it describe the risks of each treatment? | 1–5 point |
| 12 Does it describe what would happen if no treatment is used? | 1–5 point |
| 13 Does it describe how the treatment choices affect overall quality of life? | 1–5 point |
| 14 Is it clear that there may be more than one possible treatment choice? | 1–5 point |
| 15 Does it provide support for shared decision making? | 1–5 point |
| 16 Based on the answers to all of the above questions, rate the overall quality of the publication as a source of information about treatment choices. | 1–5 point |
|
|
|
| Poor quality, poor flow of the site, most information missing, not at all useful for patients | 1 |
| Generally poor quality and poor flow, some information listed but many important topics missing, of very limited use to patients | 2 |
| Moderate quality, suboptimal flow, some important information is adequately discussed but others poorly discussed, somewhat useful for patients | 3 |
| Good quality and generally good flow, most of the relevant information is listed, but some topics not covered, useful for patients | 4 |
| Excellent quality and excellent flow, very useful for patients | 5 |
Note:
JAMA, Journal of American Medical Association; GQS, Global Quality Score.
Figure 1Flow diagram for review of Youtube videos on post-COVID pain.
Comparison of the content of videos over the years.
| Video content/years | 2020, | 2021, | 2022, |
| |
|---|---|---|---|---|---|
| Animation | + | 1 (3.2%) | 12 (28.6%) | 9 (33.8%) |
|
| − | 30 (96.8%) | 30 (71.4%) | 18(66.7%) | ||
| Etiology | + | 10 (32.3%) | 21 (50%) | 14 (51.9%) | 0.281 |
| – | 21 (67.7%) | 21 (50%) | 13 (48.1%) | ||
| Diagnose | + | 11 (35.5%) | 18 (42.9%) | 3 (11.1%) |
|
| – | 20 (64.5%) | 24 (57.1%) | 24 (88.9%) | ||
| Non-pain symptom | + | 20 (64.5%) | 31 (73.8%) | 21 (77.8%) | 0.502 |
| – | 11 (35.5%) | 11 (26.2%) | 6 (22.2%) | ||
| Treatment | + | 24 (77.4%) | 32 (76.2%) | 23 (82.5%) | 0.648 |
| – | 7 (22.6%) | 10 (23.8%) | 4 (14.8%) | ||
| Exercise | + | 15 (48.4%) | 19 (45.2%) | 14 (51.9%) | 0.865 |
| – | 16 (51.6%) | 23 (54.8%) | 12 (48.1%) | ||
| Prevention | + | 12 (38.7%) | 17 (40.5%) | 9 (33.3%) | 0.833 |
| – | 19 (61.3%) | 25 (59.5%) | 18 (66.7%) | ||
| Risk factors | + | 5 (16.1%) | 7 (16.7%) | 5 (18.5%) | 0.968 |
| – | 26 (83.9%) | 35 (83.3%) | 22 (81.5%) | ||
| Vaccine-pain relationship | + | 0 (0%) | 3 (7.1%) | 2 (7.4%) | 0.306 |
| – | 31 (100%) | 39 (92.9%) | 25 (92.6%) | ||
| JAMA | Insufficient data (1 Point) | 11 (35.5%) | 7 (16.7%) | 3 (11.1%) | 0.176 |
| Partially sufficient data (2 or 3 points) | 18 (58.1%) | 33 (78.6%) | 22 (81.5%) | ||
| Completely sufficient data (4 points) | 2 (6.5%) | 2 (4.8%) | 2 (7.4%) | ||
| GQS | Low quality (1 or 2 points) | 22 (71%) | 32 (76.2%) | 20 (74.1%) | 0.946 |
| Intermediate quality (3 points) | 5 (16.1%) | 6 (14.3%) | 3 (11.1%) | ||
| High quality (4–5 points) | 4 (12.9%) | 4 (9.5) | 4 (14.8%) | ||
| Modified DISCERN | 1 Point | 8 (25.8%) | 7 (16.7%) | 3 (11.1%) | 0.293 |
| 2 Points | 8 (25.8%) | 18 (42.9%) | 15 (55.6%) | ||
| 3 Points | 11 (35.5%) | 11 (26.2%) | 4 (14.8%) | ||
| 4 Points | 4 (12.9%) | 4 (9.5%) | 3 (11.1%) | ||
| 5 Points | 0 (0%) | 2 (4.8%) | 2 (7.4%) |
Note:
Pearson Chi-square test. GQS, Global Quality Score; JAMA, Journal of American Medical Association benchmark criteria, Bold font: statistical significance.
Video characteristics according to years and assesment parameters (mean ± standard deviation).
| Years | Follow-up | Like | Comment | Time |
|---|---|---|---|---|
| 2020 ( | 102,026.19 ± 249,481.14 | 824.67 ± 2,060.31 | 365.51 ± 773.86 | 504.16 ± 566.921 |
| 2021 ( | 44,484.73 ± 92,455.02 | 432.14 ± 1,245.57 | 106.47 ± 218.46 | 728.81 |
| 2022 ( | 30,067.40 | 825.66 ± 2,081.25 | 148.48 ± 283.33 | 821 |
|
|
| 0.413 | 0.164 | 0.098 |
|
| ||||
| Academic ( | 23,100.25 ± 52,158.631 | 618.12 ± 1,530.28 | 112 ± 270.77 | 2,052.25 ± 1,675.03 |
| Physician ( | 34,109.12 ± 43,279.41 | 462.50 ± 523.64 | 312.50 ± 505.21 | 1,014.50 ± 1,271.617 |
| Society/Professional Organization ( | 34,368.56 ± 77,429.74 | 180.37 ± 286.7 | 45.81 ± 81.87 | 580.69 ± 805.682 |
| Health-related Website ( | 56,987.78 ± 106,251.83 | 818.57 ± 2,293.62 | 144.66 ± 358.19 | 569.67 ± 688.075 |
| Patient ( | 2,502.85 ± 4,955.69 | 58.85 ± 109.59 | 27.57 ± 41.23 | 601.57 ± 303.345 |
| News ( | 104,903.64 ± 258,532.67 | 966.14 ± 2,012.83 | 382.71 ± 745.21 | 413.25 ± 326.92 |
|
|
|
|
|
|
|
| ||||
| Low quality (1 or 2 points) ( | 59,734.91 ± 171,660.96 | 528.04 ± 1,417.22 | 196.01 ± 518.03 | 503.32 ± 616.907 |
| Intermediate quality (3 points) ( | 47,206.42 ± 66,972.39 | 895.57 ± 2,624.98 | 185.07 ± 310.41 | 642 ± 723.287 |
| High quality (4–5 points) ( | 63,476.41 ± 128,961.16 | 1,199.58 ± 2,441.74 | 226.33 ± 471.23 | 1,847.67 ± 1,494.37 |
|
| 0.539 | 0.635 | 0.467 |
|
|
| ||||
| Insufficient data (1 Point) ( | 142,488.85 ± 297,662.14 | 1,205 ± 2,458.78 | 410.14 ± 891.16 | 325.24 ± 250.686 |
| Partially sufficient data (2 or 3 points) ( | 32,846.91 ± 61,027.50 | 448.10 ± 1,312.31 | 149.15 ± 291.17 | 611.9 ± 696.5 |
| Completely sufficient data (4 points) ( | 75,483.33 ± 176,893.24 | 1,331.83 ± 3,168.89 | 51.83 ± 111.94 | 2,817.83 ± 1,500.016 |
|
| 0.018 | 0.098 | 0.319 |
|
|
| ||||
| 1 Points ( | 145,217 ± 318,483.29 | 1,073.5 ± 2,455.12 | 447.05 ± 901.89 | 339.83 ± 234.648 |
| 2 Points ( | 37,995.95 ± 77,567.24 | 437.51 ± 944.61 | 131.29 ± 318.69 | 547.49 ± 663.42 |
| 3 Points ( | 34,248.03 ± 52,953.52 | 539.46 ± 1,935.72 | 136.76 ± 242.97 | 609.19 ± 780.73 |
| 4 Points ( | 31,076.27 ± 55,168.29 | 624.18 ± 1,333.74 | 230.09 ± 490.41 | 974.09 ± 651.54 |
| 5 Points ( | 109,740.75 ± 217,844.64 | 19,6375 ± 3,890.88 | 73.75 ± 137.61 | 3,322 ± 1,633.85 |
|
| 0.074 | 0.484 | 0.059 |
|
Note:
Mann Whitney U test. N, Number of videos; SD, Standart Deviation; GQS, Global Quality Score; JAMA, Journal of American Medical Association benchmark criteria, Bold font: statistical significance (p < 0.05).
Video sources by assesment parameters.
| Academic ( | Physician ( | Society/Professional Organization ( | Health-related Website ( | Patient ( | News ( |
| ||
|---|---|---|---|---|---|---|---|---|
| GQS (1–5 points) | Low quality (1or 2 points) | 0 (0%) | 6 (75%) | 9 (56.3%) | 24 (72.7%) | 7(100%) | 28 (100%) |
|
| Intermediate quality (3 points) | 0 (0%) | 1 (12.5%) | 5 (31.3%) | 8 (24.2%) | 0(0%) | 0 (0%) | ||
| High quality (4–5 points) | 8 (100%) | 1 (12.5%) | 2 (12.5%) | 1 (3%) | 0(0%) | 0 (0%) | ||
| JAMA score (0–4 points) | Insufficient data (1 point) | 0 (0%) | 0 (0%) | 0 (0%) | 6 (18.2%) | 2(28.6%) | 13 (46.4%) |
|
| Partially sufficient data (2 or 3 points) | 4 (50%) | 8 (100%) | 15 (93.8%) | 26 (78.8%) | 5 (71.4%) | 15 (53.6%) | ||
| Completely sufficient data (4 points) | 4 (50%) | 0 (0%) | 1 (6.3%) | 1 (3%) | 0 (0%) | 0 (0%) | ||
| Modified DISCERN score (0–5 points) | 1 Point | 0 (0%) | 0 (0%) | 0 (0%) | 3 (9.1%) | 1 (14.3%) | 14 (50%) |
|
| 2 Points | 0 (0%) | 4 (50%) | 5 (31.3%) | 15 (45.5%) | 5 (71.4%) | 12 (42.9%) | ||
| 3 Points | 0 (0%) | 2 (25%) | 9 (56.3%) | 12 (36.4%) | 1 (14.3%) | 2 (7.1%) | ||
| 4 Points | 5 (62.5%) | 2 (25%) | 2 (12.5%) | 2 (6.1%) | 0 (0%) | 0 (0%) | ||
| 5 Points | 3 (37.5%) | 0 (0%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) |
Notes:
Pearson Chi-square test. GQS, Global Quality Score, JAMA, Journal of American Medical Association benchmark criteria.
Bold indicates statistical significance.
Correlations between quantitative variables and scores.
| GQS | JAMA | Modified DISCERN | ||||
|---|---|---|---|---|---|---|
| r |
| r |
| r |
| |
| Number of views | −0.126 | 0.213 | −0.135 | 0.180 | −0.137 | 0.175 |
| Number of likes | 0.041 | 0.686 | 0.058 | 0.565 | 0.024 | 0.809 |
| Number of comments | −0.096 | 0.340 | −0.142 | 0.160 | −0.142 | 0.160 |
| Video duration; second | 0.500 |
| 0.528 |
| 0.470 |
|
| GQS | – |
| 0.857 |
| 0.888 |
|
| JAMA | 0.857 |
| – |
| 0.843 |
|
| Modified DISCERN | 0.888 |
| 0.843 |
| – | – |
Notes:
Pearson correlation test. GQS, Global Quality Score; JAMA, Journal of American Medical Association benchmark criteria.
Bold indicates statistical significance.
Significant correlation.
Evaluation of user parameters by continent and country.
| View | Like | Comment | Time | |
|---|---|---|---|---|
|
| ||||
| America ( | 69,896.2 ± 186,996.89 | 902.47 ± 2,162.27 | 265.3 ± 587.11 | 604.63 ± 822.72 |
| Non-america ( | 38,906.21 ± 75,310.26 | 247.35 ± 455.21 | 83.72 ± 179.3 | 819.3 ± 983.15 |
|
| 0.395 | 0.248 |
| 0.262 |
|
| ||||
| USA ( | 71,712.68 ± 191,240.08 | 929.26 ± 2,210.01 | 262.71 ± 593.19 | 603.87 ± 839.48 |
| Other ( | 38,505.75 ± 734,334.65 | 256.3 ± 461.49 | 101.22 ± 221.38 | 804.35 ± 951.29 |
|
| 0.439 | 0.436 | 0.066 | 0.361 |
Note:
Mann Whitney U test. USA, United States of America, Bold indicates statistical significance (p < 0.05).